These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23137152)

  • 1. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Baldessarini RJ
    Drug Saf; 2012 Dec; 35(12):1183; author reply 1183-4. PubMed ID: 23137152
    [No Abstract]   [Full Text] [Related]  

  • 2. Olanzapine in schizophrenia and affective disorders.
    Undurraga J; Vieta E; Tohen M; Colom F
    Drug Saf; 2012 Dec; 35(12):1185-6; author reply 1186. PubMed ID: 23137154
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Zhornitsky S; Brunelle S; Stip E
    Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine: a critical review of recent literature.
    Buckley PF
    Expert Opin Pharmacother; 2005 Oct; 6(12):2077-89. PubMed ID: 16197360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatological side effects of olanzapine.
    Varghese ST; Balhara YP; Shyamsunder S; Mondal A
    Indian J Med Sci; 2005 Jul; 59(7):320-1. PubMed ID: 16062020
    [No Abstract]   [Full Text] [Related]  

  • 6. Olanzapine-induced oculogyric crisis in a patient with schizophrenia.
    Chakraborty R; Chatterjee A; Chaudhury S
    Indian J Med Sci; 2008 Jun; 62(6):238-9. PubMed ID: 18603742
    [No Abstract]   [Full Text] [Related]  

  • 7. [A combination of antidepressants and neuroleptics in the treatment of affective disorders and schizophrenia: indications, side effects and complications].
    Andrusenko MP; Morozova MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(11):60-5. PubMed ID: 11247192
    [No Abstract]   [Full Text] [Related]  

  • 8. Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia.
    Kulkarni G; Narayanaswamy JC; Math SB
    Indian J Pharmacol; 2012; 44(5):649-50. PubMed ID: 23112432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study.
    Novick D; Haro JM; Suarez D; Marques-Teixeira J; Naber D
    Int Clin Psychopharmacol; 2008 Jul; 23(4):203-8. PubMed ID: 18545058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of hyperglycemia in patients treated with olanzapine.
    Misawa F; Miyaji S; Fuji Y; Miyata R; Obi K; Koshiishi F; Shimada H; Fukuda M; Koizumi T
    J Clin Psychiatry; 2004 Mar; 65(3):443-4. PubMed ID: 15096088
    [No Abstract]   [Full Text] [Related]  

  • 11. Olanzapine-associated pica in a schizophrenia patient.
    Huang JH; Shiah IS; Lee WK; Tzang RF; Chang KJ
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):444. PubMed ID: 20653915
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia.
    Bhanji NH; Margolese HC
    Can J Psychiatry; 2004 May; 49(5):343. PubMed ID: 15198472
    [No Abstract]   [Full Text] [Related]  

  • 14. Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine".
    Reis de Sá A; Elkis H
    Braz J Psychiatry; 2007 Mar; 29(1):90; author reply 91. PubMed ID: 17435940
    [No Abstract]   [Full Text] [Related]  

  • 15. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
    Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G
    Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis.
    Bloechliger M; Rüegg S; Jick SS; Meier CR; Bodmer M
    CNS Drugs; 2015 Jul; 29(7):591-603. PubMed ID: 26242478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.
    Chandrasena R; Dvoráková D; Lee SI; Loza N; Mosolov SN; Osváth P; Pregelj P; Walton RJ; Karagianis J; Treuer T
    Int J Clin Pract; 2009 Aug; 63(8):1249-58. PubMed ID: 19558486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes and psychosis: olanzapine may not be the culprit.
    Levy P
    Hong Kong Med J; 2007 Aug; 13(4):335. PubMed ID: 17664543
    [No Abstract]   [Full Text] [Related]  

  • 19. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms.
    Waddington JL
    Int Rev Neurobiol; 1989; 31():297-353. PubMed ID: 2574716
    [No Abstract]   [Full Text] [Related]  

  • 20. Olanzapine metabolic side effects: a weight gain issue?
    Carulli L; Mazzi F; Rondinella S; Bertolotti M
    Intern Emerg Med; 2008 Sep; 3(3):237-40. PubMed ID: 18369533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.